亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study

医学 肝细胞癌 队列 内科学 乙型肝炎病毒 胃肠病学 HBeAg 免疫学 肿瘤科 病毒 乙型肝炎表面抗原
作者
Qing-Jing Chen,Kongying Lin,Zhi-Wen Lin,Bing Zhang,Ming-Qiang Liu,Jianxi Zhang,Qi-Zhen Huang,Kecan Lin,Jinyu Zhang,Fuqun Wei,Peng-Hui You,You Song,Jiang Ya-bin,Hui Zhang,Zhi-Qing Cheng,Cong-Ren Wang,Yongyi Zeng
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:125 (Pt A): 111098-111098 被引量:5
标识
DOI:10.1016/j.intimp.2023.111098
摘要

The efficacy and safety of tyrosine kinase inhibitors (TKIs) combined with anti-PD-1 antibodies (α-PD-1) in advanced hepatocellular carcinoma (HCC) with high hepatitis B virus (HBV) DNA levels (>500 IU/mL) remain unclear. We retrospectively assessed patients from seven medical institutions diagnosed with HBV-related HCC, undergoing treatment with TKIs and α-PD-1 in conjunction with antiviral therapies. Based on HBV-DNA levels, patients were categorized into either high (HHBV-DNA, >500 IU/mL) or low HBV-DNA (LHBV-DNA, ≤500 IU/mL) cohorts Propensity score matching (PSM) was used to minimize baseline imbalance between groups. 149 patients were included, with 66 patients exhibiting HBV-DNA > 500 IU/mL and 83 patients presenting HBV-DNA ≤ 500 IU/mL. Compared with the LHBV-DNA cohort, the HHBV-DNA cohort had a greater incidence of serum HBeAg positivity, tumor diameter ≥ 10 cm, and vascular invasion. Following PSM, 57 individuals were enrolled in each group. Oncological outcomes were comparable between HHBV-DNA and LHBV-DNA cohorts before and after PSM. Before PSM, the median PFS and OS were 6.1 months and 17.5 months in the HHBV-DNA cohort and 6.7 months and 19.3 months in the LHBV-DNA cohort (all P > 0.05). After PSM, the median PFS and OS were 6.0 months and 19.5 months in the HHBV-DNA cohort and 6.0 months and 17.1 months in the LHBV-DNA cohort, respectively (all P > 0.05). Safety profiles were equivalent across cohorts with no fatal incidents reported. Seven patients (4.7 %) had HBV reactivation. 1 (0.7 %) from HHBV-DNA and 6 (4.0 %) from LHBV-DNA (P = 0.134). Only one patient developed HBV-related hepatitis. The effectiveness and safety of TKIs plus α-PD-1 in advanced HCC with HBV-DNA > 500 IU/mL were not compromised in the context of concomitant antiviral therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
充电宝的应助被可乐采纳,获得10
2秒前
YX给YX的求助进行了留言
3秒前
4秒前
完美的睿渊完成签到,获得积分10
5秒前
rongrongrong完成签到,获得积分10
7秒前
JamesPei的应助被Brightfuture采纳,获得10
9秒前
10秒前
11秒前
儒雅傲人完成签到,获得积分10
13秒前
打打的应助被虚幻的凌珍采纳,获得10
14秒前
真实的瑾瑜完成签到 ,获得积分10
16秒前
科研通AI6.3的应助被风趣含双采纳,获得10
17秒前
mohamed123发布了新的文献求助10
17秒前
18秒前
18秒前
啥子组蛋白完成签到,获得积分10
19秒前
KKIII发布了新的文献求助10
20秒前
Brightfuture发布了新的文献求助10
23秒前
24秒前
小蘑菇的应助被儒雅傲人采纳,获得10
25秒前
田様的应助被儒雅傲人采纳,获得10
25秒前
28秒前
沉默的涔完成签到 ,获得积分10
30秒前
Ava的应助被儒雅傲人采纳,获得10
31秒前
CipherSage的应助被儒雅傲人采纳,获得10
31秒前
慕青的应助被儒雅傲人采纳,获得10
31秒前
大个的应助被儒雅傲人采纳,获得10
31秒前
CipherSage的应助被儒雅傲人采纳,获得10
31秒前
Jasper的应助被儒雅傲人采纳,获得10
31秒前
科研通AI6.3的应助被儒雅傲人采纳,获得10
31秒前
小蘑菇的应助被儒雅傲人采纳,获得10
31秒前
molihuakai的应助被儒雅傲人采纳,获得10
31秒前
Maestro_S的应助被儒雅傲人采纳,获得30
32秒前
36秒前
干净的中心完成签到,获得积分10
36秒前
星辰大海的应助被儒雅傲人采纳,获得10
37秒前
CipherSage的应助被儒雅傲人采纳,获得10
37秒前
华仔的应助被儒雅傲人采纳,获得10
38秒前
充电宝的应助被儒雅傲人采纳,获得10
38秒前
天天快乐的应助被儒雅傲人采纳,获得10
38秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565479
关于积分的说明 21780029
捐赠科研通 7764837
什么是DOI,文献DOI怎么找? 3431499
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476579